Health Condition 1: C910- Acute lymphoblastic leukemia [ALL] Health Condition 2: C920- Acute myeloblastic leukemia Health Condition 3: C925- Acute myelomonocytic leukemia Health Condition 4: C924- Acute promyelocytic leukemia Health Condition 5: C919- Lymphoid leukemia, unspecified Health Condition 6: C929- Myeloid leukemia, unspecified Health Condition 7: C91Z- Other lymphoid leukemia Health Condition 8: C92Z- Other myeloid leukemia Health Condition 9: C96Z- Other specified malignant neoplasms
Conditions
Interventions
Intervention1: Buffy Coat Pooled Platelets: 1 unit (200-300ml) of Buffy Coat Pooled Platelets will be transfused intravenously to hemato-oncology patients with thrombocytopenia. The platelet increment
Sponsors
Dr Juhi Bhatia
Eligibility
Inclusion criteria
Inclusion criteria: All hemato-oncology patients admitted to the Department of Medical Oncology-Hematology, AIIMS Rishikesh, who will be requiring more than one adult dose of platelet transfusion during their single admission at AIIMS Rishikesh.
Exclusion criteria
Exclusion criteria: 1. Patients requiring less than 2 adult doses of platelet transfusion during the course of their single admission at AIIMS Rishikesh. 2. Patients not willing to be a part of the study. 3. Patients requiring multiple transfusions of random donor platelets but requiring less than one adult dose of platelet concentrate during the course of a single admission.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Increment in platelet count in patients with buffy coat pooled platelets and apheresis platelet concentrate transfusion 2. Analysis of the transfusion reactions after transfusion of both the productsTimepoint: 1 hour and 24 hours post transfusion | — |
Secondary
| Measure | Time frame |
|---|---|
| Analysis of the in vitro quality parameters of buffy coat pooled platelet concentrate and apheresis platelet concentrateTimepoint: Day 1 and Day 5 | — |
Countries
India
Contacts
Public ContactDr Juhi Bhatia
AIIMS Rishikesh
Outcome results
None listed